<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b29f/10482109/5bec1bc086aa/fimmu-14-1197630-g004.jpg"/> </div> <div class="text-side"> <h1>Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy.</h1> <p>IL-17-expressing cells are differently modulated in the skin lesion and in the circulation of melanoma patients developing vitiligo during anti-PD-1 therapy. (A) Representative images of the immunohistochemistry (panels a to d) and immunofluorescence (panels e, f) analysis performed using antibodies directed against CD56 (panels a–c), IL-17 (panels d–f) and TCR alpha V 7.2 (panels g–i) on normal skin biopsies and on biopsies from patients affected by vitiligo without melanoma (vitiligo) and who developed vitiligo during immunotherapy (vitiligo DI). Magnification 200x. (B) Quantitative analyses of immunohistochemical staining. The mean value + standard error of the mean (SEM) of the cell count obtained for five different fields is shown, ***p&lt;0.05 as assessed by Kruskal-Wallis test.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37680638/" target="_blank">37680638</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>